On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
MSCs as “Therapeutic Workhouses” in the Era of Regenerative Medicine
MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform
LONDON, UK and BOCA RATON, FL, — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell register and is now driving forward cell therapy advancements, announced the signing of an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio’s CORDStrom™ platform, the industry’s most advanced Mesenchymal Stromal Cell (MSC) technology designed to deliver consistent, scalable, and “off-the-shelf” cellular therapies which are suitable for supply in UK, EU and US, as well as other global regions. [Read more…]
Factor Bioscience to Reveal Two Novel iPSC-derived MSC (iMSC) Programs at ASGCT 2026
- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
BioEden: How Dental Stem Cells Will Impact Our Future
In this interview with Tony Veverka, Chief Group Executive of BioEden, Mr. Veverka discusses how dental stem cells will impact our future. BioEden is a global stem cell storage company with laboratories in the UK and USA and sales operations in 19 countries. BioEden is also the world’s first international biobank company to collect, assess, and cryogenically store living stem cells from deciduous baby teeth.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 59
- Next Page »